Securities code: 688289 securities abbreviation: Sansure Biotech Inc(688289) Announcement No.: 2022-008 Sansure Biotech Inc(688289)
Announcement on the implementation results of share repurchase
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
1、 Review and approval of repurchase and contents of repurchase plan
Sansure Biotech Inc(688289) (hereinafter referred to as “the company”) held the eighth extraordinary meeting of the first board of directors in 2021 on October 21, 2021, deliberated and adopted the proposal on repurchase of shares of the company by means of centralized bidding transaction, and agreed that the company would repurchase shares of the company by means of centralized bidding transaction, with a total repurchase fund of no less than 200 million yuan (including), The repurchase price shall not exceed RMB 260 million (inclusive), and the repurchase price shall not exceed RMB 70 / share (inclusive). The repurchase period shall be within 6 months from the date when the board of directors of the company deliberates and approves the repurchase plan. For details, please refer to the company’s disclosure on the website of Shanghai Stock Exchange (www.sse. Com. CN.) on October 22, 2021 and November 3, 2021 The Sansure Biotech Inc(688289) announcement on the plan of repurchasing the company’s shares by means of centralized bidding transaction (Announcement No.: 2021-062) and the Sansure Biotech Inc(688289) report on repurchasing shares by means of centralized bidding transaction (Announcement No.: 2021-073). After the implementation of the company’s quarterly equity distribution in 2021, the upper limit of the company’s share repurchase price in the form of centralized bidding transaction is adjusted from no more than 70.00 yuan / share (inclusive) to no more than 69.25 yuan / share (inclusive). For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on December 4, 2021 A notice on the adjustment of the price cap of repurchase shares after the implementation of quarterly equity allocation in 2021 (Announcement No.: 2021-091) is disclosed.
2、 Implementation of repurchase
(I) on November 2, 2021, the company implemented share repurchase for the first time, and disclosed the announcement on the progress of Sansure Biotech Inc(688289) initial repurchase of company shares by means of centralized bidding transaction and share repurchase (Announcement No.: 2021-074) on November 3, 2021.
(II) on February 8, 2022, the company completed this repurchase and has actually repurchased 4791299 shares of the company, accounting for 1.20% of the total share capital of the company, with the highest repurchase price of 69.20 yuan / share, the lowest repurchase price of 49.97 yuan / share, the average repurchase price of about 54.29 yuan / share and the total amount of funds used of 260109720.30 yuan.
(III) there is a difference between the actual implementation of this repurchase plan and the repurchase plan originally disclosed. The part of the total amount of funds actually used by the company exceeding the upper limit of the total amount of repurchase funds in the plan is the interest generated from the available balance in the special securities account for repurchase. The company uses the interest for repurchase, as well as the transaction commissions, transfer fees and other transaction expenses generated by repurchase.
(IV) the funds used in this share repurchase are the company’s own funds and will not have a significant impact on the company’s business activities, financial status and future development. This repurchase will not lead to changes in the company’s control. After the repurchase, the company’s equity distribution meets the conditions of listed companies and will not affect the company’s listing status.
3、 Shares bought and sold by relevant entities during the repurchase period
On October 22, 2021, the company disclosed the repurchase of shares for the first time. For details, see Sansure Biotech Inc(688289) announcement on the repurchase of shares of the company by means of centralized bidding transaction (Announcement No.: 2021-062). As of the disclosure of this announcement, the company’s directors, supervisors, controlling shareholders, actual controllers and share repurchase proponents bought and sold the company’s shares during this period and the reasons are as follows:
Based on his confidence in the company’s future development and recognition of the company’s long-term investment value, Mr. Dai Lizhong, the actual controller and chairman of the company, increased his holdings of 1584206 shares, accounting for 0.40% of the company’s total share capital. Due to his own financial needs and arrangements, Mr. Zhu Jinwei, the director of the company, reduced his holdings of 5800000 shares of the company, accounting for 1.45% of the total share capital of the company.
4、 Disposal arrangement of repurchased shares
Before and after the implementation of the share repurchase plan, the total share capital of the company has not changed; After the implementation of the share repurchase plan, 4791299 shares in the special securities account for repurchase are included in the shares with unlimited sales conditions of the company.
The company has repurchased 4791299 shares this time, which will be fully used for employee stock ownership plan or equity incentive at an appropriate time in the future. During the period when the above repurchased shares are deposited in the special securities account for share repurchases of the company, they do not enjoy the voting rights of the general meeting of shareholders, profit distribution, conversion of provident fund into share capital, subscription of new shares, allotment of shares, pledge and other rights. If the company fails to implement the above-mentioned purposes and complete the transfer within three years after the issuance of this announcement, it will perform the procedures for reducing the registered capital according to law, and the non transferred shares will be cancelled.
Subsequently, the company will use the repurchased shares according to the purpose of disclosure, and perform the decision-making procedures and information disclosure obligations as required.
It is hereby announced.
Sansure Biotech Inc(688289) board of directors February 9, 2022
